Compare Moderna, Inc. (MRNA) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Union Pacific Corporation — how do they compare? Moderna, Inc. trades at $137.23 (market cap $56.02B), while Union Pacific Corporation trades at $285.05 (market cap $171.36B). The key difference: Union Pacific Corporation is far larger — about 3.1× Moderna, Inc.'s market cap, and Union Pacific Corporation pays a 1.97% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | UNP | |
|---|---|---|
Market Cap | $56.02B | $171.36B |
Sector | Health | Industrials |
52-Week High | $174.38 | $310.62 |
52-Week Low | $22.36 | $214.91 |
Enterprise Value | $52.17B | $200.42B |
Dividend Yield | — | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
Union Pacific (UNP) trades at $288.45, down 0.4% with a bearish technical signal despite strong fundamentals. The company reported solid Q2 2026 earnings beat ($3.41 vs $3.26 expected) and maintains robust profitability with 28.85% net margin and 39.7% ROE. Recent news highlights progress on the Norfolk Southern merger, expected to close by late 2027, while institutional activity shows mixed positioning with some funds increasing stakes while others reduced exposure.
The stock offers upside to the $334.33 consensus price target with 58.7% analyst buy ratings, though technical resistance near $290-294 and merger regulatory risks warrant monitoring. Strong cash flow generation ($9.29B operating cash flow in 2025) and dividend payments ($1.42 declared for H2-26) support shareholder returns, while debt levels remain manageable at 46.06% debt-to-asset ratio.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
